CA2673435C - Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline - Google Patents
Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline Download PDFInfo
- Publication number
- CA2673435C CA2673435C CA2673435A CA2673435A CA2673435C CA 2673435 C CA2673435 C CA 2673435C CA 2673435 A CA2673435 A CA 2673435A CA 2673435 A CA2673435 A CA 2673435A CA 2673435 C CA2673435 C CA 2673435C
- Authority
- CA
- Canada
- Prior art keywords
- disorder
- salt
- succinate salt
- depressive
- dementia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000003890 succinate salts Chemical class 0.000 title claims abstract description 58
- AZEXWHKOMMASPA-UHFFFAOYSA-N 2-{[4-(1-methyl-4-pyridin-4-yl-1h-pyrazol-3-yl)phenoxy]methyl}quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(C)C=C1C1=CC=NC=C1 AZEXWHKOMMASPA-UHFFFAOYSA-N 0.000 title abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 239000003937 drug carrier Substances 0.000 claims abstract description 7
- 208000028017 Psychotic disease Diseases 0.000 claims description 28
- 208000035475 disorder Diseases 0.000 claims description 25
- 206010012289 Dementia Diseases 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 19
- 230000004770 neurodegeneration Effects 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 17
- 201000000980 schizophrenia Diseases 0.000 claims description 17
- 208000020401 Depressive disease Diseases 0.000 claims description 16
- 208000024254 Delusional disease Diseases 0.000 claims description 15
- 208000002851 paranoid schizophrenia Diseases 0.000 claims description 15
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 15
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 13
- 208000019901 Anxiety disease Diseases 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims description 12
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims description 12
- 206010013663 drug dependence Diseases 0.000 claims description 12
- 230000036651 mood Effects 0.000 claims description 12
- 208000023105 Huntington disease Diseases 0.000 claims description 10
- 208000019022 Mood disease Diseases 0.000 claims description 10
- 208000016285 Movement disease Diseases 0.000 claims description 10
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 208000024714 major depressive disease Diseases 0.000 claims description 10
- 208000018737 Parkinson disease Diseases 0.000 claims description 9
- 201000002545 drug psychosis Diseases 0.000 claims description 9
- 238000002844 melting Methods 0.000 claims description 9
- 230000008018 melting Effects 0.000 claims description 9
- 208000011117 substance-related disease Diseases 0.000 claims description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 7
- 206010007776 catatonia Diseases 0.000 claims description 7
- 229910052802 copper Inorganic materials 0.000 claims description 7
- 239000010949 copper Substances 0.000 claims description 7
- 208000022821 personality disease Diseases 0.000 claims description 7
- 230000002490 cerebral effect Effects 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- 230000008733 trauma Effects 0.000 claims description 6
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 5
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 5
- 201000004810 Vascular dementia Diseases 0.000 claims description 5
- 229940025084 amphetamine Drugs 0.000 claims description 5
- 229960003920 cocaine Drugs 0.000 claims description 5
- 208000020186 Schizophreniform disease Diseases 0.000 claims description 4
- 230000007000 age related cognitive decline Effects 0.000 claims description 4
- 230000003001 depressive effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
- 208000022610 schizoaffective disease Diseases 0.000 claims description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 3
- 208000031091 Amnestic disease Diseases 0.000 claims description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 206010010904 Convulsion Diseases 0.000 claims description 3
- 206010012218 Delirium Diseases 0.000 claims description 3
- 206010049669 Dyscalculia Diseases 0.000 claims description 3
- 208000013016 Hypoglycemia Diseases 0.000 claims description 3
- 208000020358 Learning disease Diseases 0.000 claims description 3
- 206010026749 Mania Diseases 0.000 claims description 3
- 208000036626 Mental retardation Diseases 0.000 claims description 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 101710138657 Neurotoxin Proteins 0.000 claims description 3
- 206010070606 Post stroke depression Diseases 0.000 claims description 3
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims description 3
- 208000022372 Reading disease Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 3
- 208000028683 bipolar I disease Diseases 0.000 claims description 3
- 208000022257 bipolar II disease Diseases 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 208000026725 cyclothymic disease Diseases 0.000 claims description 3
- 206010058319 dysgraphia Diseases 0.000 claims description 3
- 206010013932 dyslexia Diseases 0.000 claims description 3
- 208000024732 dysthymic disease Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 208000028329 epileptic seizure Diseases 0.000 claims description 3
- 239000000380 hallucinogen Substances 0.000 claims description 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 3
- 230000001505 hypomanic effect Effects 0.000 claims description 3
- 238000007917 intracranial administration Methods 0.000 claims description 3
- 201000003723 learning disability Diseases 0.000 claims description 3
- 239000002581 neurotoxin Substances 0.000 claims description 3
- 231100000618 neurotoxin Toxicity 0.000 claims description 3
- 229940005483 opioid analgesics Drugs 0.000 claims description 3
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims description 3
- 229950010883 phencyclidine Drugs 0.000 claims description 3
- 231100000572 poisoning Toxicity 0.000 claims description 3
- 230000000607 poisoning effect Effects 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 2
- 240000004308 marijuana Species 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 33
- 241000124008 Mammalia Species 0.000 abstract description 28
- 210000003169 central nervous system Anatomy 0.000 abstract description 7
- 150000001875 compounds Chemical class 0.000 description 14
- 239000007787 solid Substances 0.000 description 12
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 9
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 8
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000019771 cognition Effects 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- -1 nucleotide monophosphates Chemical class 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 108010044467 Isoenzymes Proteins 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 208000019906 panic disease Diseases 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000007848 Alcoholism Diseases 0.000 description 2
- 208000029197 Amphetamine-Related disease Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000218236 Cannabis Species 0.000 description 2
- 208000022497 Cocaine-Related disease Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010078321 Guanylate Cyclase Proteins 0.000 description 2
- 102000014469 Guanylate cyclase Human genes 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000026251 Opioid-Related disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 201000006145 cocaine dependence Diseases 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 201000005040 opiate dependence Diseases 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 125000001572 5'-adenylyl group Chemical group C=12N=C([H])N=C(N([H])[H])C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010010219 Compulsions Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026345 acute stress disease Diseases 0.000 description 1
- 238000011292 agonist therapy Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000001010 olfactory tubercle Anatomy 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000001907 polarising light microscopy Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001144 powder X-ray diffraction data Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000014786 regulation of synaptic transmission Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000016686 tic disease Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87126006P | 2006-12-21 | 2006-12-21 | |
| US60/871,260 | 2006-12-21 | ||
| PCT/IB2007/003819 WO2008084299A1 (en) | 2006-12-21 | 2007-12-03 | Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2673435A1 CA2673435A1 (en) | 2008-07-17 |
| CA2673435C true CA2673435C (en) | 2012-10-09 |
Family
ID=39321475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2673435A Expired - Fee Related CA2673435C (en) | 2006-12-21 | 2007-12-03 | Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8283471B2 (enExample) |
| EP (1) | EP2125786B1 (enExample) |
| JP (1) | JP5254602B2 (enExample) |
| KR (2) | KR20090092338A (enExample) |
| CN (1) | CN101611029B (enExample) |
| AR (1) | AR064417A1 (enExample) |
| AT (1) | ATE502028T1 (enExample) |
| AU (1) | AU2007343135B2 (enExample) |
| BR (1) | BRPI0720936A2 (enExample) |
| CA (1) | CA2673435C (enExample) |
| CY (1) | CY1111919T1 (enExample) |
| DE (1) | DE602007013294D1 (enExample) |
| DK (1) | DK2125786T3 (enExample) |
| ES (1) | ES2360014T3 (enExample) |
| IL (1) | IL199389A (enExample) |
| MX (1) | MX2009006528A (enExample) |
| NZ (1) | NZ577716A (enExample) |
| PL (1) | PL2125786T3 (enExample) |
| PT (1) | PT2125786E (enExample) |
| RU (1) | RU2430918C2 (enExample) |
| SI (1) | SI2125786T1 (enExample) |
| TW (1) | TWI359660B (enExample) |
| WO (1) | WO2008084299A1 (enExample) |
| ZA (1) | ZA200904230B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010033045A1 (en) * | 2008-09-16 | 2010-03-25 | Igor Anatolievich Pomytkin | Compositions and methods for prevention or treatment of beta amyloid deposition |
| TWI396689B (zh) | 2008-11-14 | 2013-05-21 | Amgen Inc | 作為磷酸二酯酶１０抑制劑之吡衍生物 |
| US20120214842A1 (en) * | 2011-02-18 | 2012-08-23 | Exonhit Therapeutics Sa | Methods for treating diseases of the retina |
| EP2975037A4 (en) | 2013-03-15 | 2016-08-10 | Daiichi Sankyo Co Ltd | benzothiophene derivative |
| US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
| KR102233916B1 (ko) * | 2019-05-28 | 2021-03-30 | 주식회사 엘지생활건강 | Pq1 숙신산을 포함하는 피부 보습, 주름 개선 및 탄력 증진용 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4105551A1 (de) * | 1991-02-22 | 1992-08-27 | Bayer Ag | 2-substituierte chinoline, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| EA011451B1 (ru) * | 2001-02-12 | 2009-04-28 | Уайт | Новая соль сукцинат о-десметилвенлафаксина |
| IL161326A0 (en) * | 2001-11-29 | 2004-09-27 | Pfizer Prod Inc | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| CN1608062A (zh) * | 2001-12-12 | 2005-04-20 | 辉瑞产品公司 | E－2－甲氧基－n－(3－{4－[3－甲基－4－(6－甲基－吡啶－3－基氧基) －苯氨基]－喹唑啉－6基}－烯丙基)－乙酰胺的盐，其制备和抗癌用途 |
| CA2536073A1 (en) * | 2003-08-18 | 2005-02-24 | H. Lundbeck A/S | Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
| WO2006072828A2 (en) * | 2005-01-07 | 2006-07-13 | Pfizer Products Inc. | Heteroaromatic quinoline compounds and their use as pde10 inhibitors |
| WO2006078825A2 (en) | 2005-01-21 | 2006-07-27 | Cabot Corporation | Processes for forming nanoparticles |
| AU2006329849A1 (en) * | 2005-12-16 | 2007-07-05 | Wyeth | Lyophilized compositions of a triazolopyrimidine compound |
-
2007
- 2007-12-03 CN CN200780051566.5A patent/CN101611029B/zh not_active Expired - Fee Related
- 2007-12-03 EP EP07858987A patent/EP2125786B1/en not_active Not-in-force
- 2007-12-03 AU AU2007343135A patent/AU2007343135B2/en not_active Ceased
- 2007-12-03 CA CA2673435A patent/CA2673435C/en not_active Expired - Fee Related
- 2007-12-03 SI SI200730561T patent/SI2125786T1/sl unknown
- 2007-12-03 PL PL07858987T patent/PL2125786T3/pl unknown
- 2007-12-03 DK DK07858987.6T patent/DK2125786T3/da active
- 2007-12-03 KR KR1020097015193A patent/KR20090092338A/ko not_active Ceased
- 2007-12-03 MX MX2009006528A patent/MX2009006528A/es active IP Right Grant
- 2007-12-03 AT AT07858987T patent/ATE502028T1/de active
- 2007-12-03 KR KR1020127009903A patent/KR20120043775A/ko not_active Ceased
- 2007-12-03 RU RU2009123347/04A patent/RU2430918C2/ru not_active IP Right Cessation
- 2007-12-03 PT PT07858987T patent/PT2125786E/pt unknown
- 2007-12-03 BR BRPI0720936-3A patent/BRPI0720936A2/pt not_active IP Right Cessation
- 2007-12-03 ES ES07858987T patent/ES2360014T3/es active Active
- 2007-12-03 NZ NZ577716A patent/NZ577716A/xx not_active IP Right Cessation
- 2007-12-03 WO PCT/IB2007/003819 patent/WO2008084299A1/en not_active Ceased
- 2007-12-03 US US12/515,612 patent/US8283471B2/en not_active Expired - Fee Related
- 2007-12-03 DE DE602007013294T patent/DE602007013294D1/de active Active
- 2007-12-18 AR ARP070105692A patent/AR064417A1/es not_active Application Discontinuation
- 2007-12-19 JP JP2007327323A patent/JP5254602B2/ja not_active Expired - Fee Related
- 2007-12-20 TW TW096148920A patent/TWI359660B/zh not_active IP Right Cessation
-
2009
- 2009-06-16 IL IL199389A patent/IL199389A/en active IP Right Review Request
- 2009-06-17 ZA ZA200904230A patent/ZA200904230B/xx unknown
-
2011
- 2011-05-17 CY CY20111100481T patent/CY1111919T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090092338A (ko) | 2009-08-31 |
| BRPI0720936A2 (pt) | 2014-03-11 |
| AR064417A1 (es) | 2009-04-01 |
| ATE502028T1 (de) | 2011-04-15 |
| JP5254602B2 (ja) | 2013-08-07 |
| AU2007343135A1 (en) | 2008-07-17 |
| IL199389A (en) | 2014-01-30 |
| CN101611029A (zh) | 2009-12-23 |
| HK1134670A1 (en) | 2010-05-07 |
| EP2125786B1 (en) | 2011-03-16 |
| PL2125786T3 (pl) | 2011-07-29 |
| EP2125786A1 (en) | 2009-12-02 |
| SI2125786T1 (sl) | 2011-05-31 |
| TWI359660B (en) | 2012-03-11 |
| MX2009006528A (es) | 2009-06-26 |
| WO2008084299A1 (en) | 2008-07-17 |
| NZ577716A (en) | 2012-10-26 |
| PT2125786E (pt) | 2011-04-21 |
| US20100063089A1 (en) | 2010-03-11 |
| CY1111919T1 (el) | 2015-11-04 |
| ES2360014T3 (es) | 2011-05-31 |
| RU2009123347A (ru) | 2011-01-27 |
| ZA200904230B (en) | 2010-04-28 |
| TW200833337A (en) | 2008-08-16 |
| AU2007343135B2 (en) | 2013-03-21 |
| JP2008208114A (ja) | 2008-09-11 |
| RU2430918C2 (ru) | 2011-10-10 |
| CA2673435A1 (en) | 2008-07-17 |
| DK2125786T3 (da) | 2011-05-09 |
| DE602007013294D1 (de) | 2011-04-28 |
| KR20120043775A (ko) | 2012-05-04 |
| CN101611029B (zh) | 2014-09-10 |
| US8283471B2 (en) | 2012-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8741899B2 (en) | (4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo-[1,2-a]pyrazin-2(1H)-ylcarbonyl]-benzenesulfonamide, and pharmaceutically acceptable salts thereof | |
| CA2654394A1 (en) | Tricyclic heteroaryl compounds as pde10 inhibitors | |
| JP2023051962A (ja) | ９，１０，１１，１２－テトラヒドロ－８ｈ－［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２－ｆ］キノリン－８－オン化合物およびその使用 | |
| AU2007343135B2 (en) | Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl) phenoxy)methyl)quinoline | |
| KR20140041583A (ko) | Ｌｒｒｋ2 키나제 활성의 억제제 | |
| CA2757231A1 (en) | 1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators | |
| US12103921B2 (en) | Chemical compounds | |
| EA017402B1 (ru) | [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины, их формы, способы получения соединений, фармацевтические композиции, содержащие эти соединения, и их применение | |
| AU2019459552A1 (en) | Dihydro-pyrrolo-pyrimidine selective JAK2 inhibitor | |
| JP7018944B2 (ja) | ＰＤＥ２阻害剤としての［１，２，４］トリアゾロ［１，５－ａ］ピリミジン化合物 | |
| TW201028398A (en) | Quinolone compound and pharmaceutical composition | |
| WO2014150981A1 (en) | Inhibitors of lrrk2 kinase activity | |
| WO2013161848A1 (ja) | 新規１，２，４－トリアジン誘導体 | |
| AU2022209175A9 (en) | Indole derivatives as kinase inhibitors | |
| HK1134670B (en) | Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline | |
| CN115636832A (zh) | 嘧啶并吡咯类化合物的可药用盐、晶型及其制备方法 | |
| EA043251B1 (ru) | Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение | |
| TW201600520A (zh) | 雜環化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20191203 |